Gene Therapy Platforms May Require Less Preclinical Data, Gottlieb Says
Executive Summary
US FDA's preclinical policies should be 'more closely matched to the complexion of modern technologies,' commissioner explains.
You may also be interested in...
Payers Could Guarantee Biosimilar Market Share, FDA's Gottlieb Suggests
Commissioner worries that fewer drugs may enter market in some categories because of drug development costs, and offers some post-market strategies for encouraging biosimilar development.
Payers Could Guarantee Biosimilar Market Share, FDA's Gottlieb Suggests
Commissioner worries that fewer drugs may enter market in some categories because of drug development costs, and offers some post-market strategies for encouraging biosimilar development.
US FDA To Publish Own Datasets In Latest Signal Of Enhanced Transparency
Adverse event reporting data will also be more readily available, Commissioner Scott Gottlieb says.